NORTHWEST BIOTHERAPEUTICS INC (NWBO) Form 10-Q — Nov 13, 2026
Northwest Biotherapeutics reported a Q3 2026 net loss of $28.8 million and a nine-month net loss of $41.1 million, improved from $61.6 million a year earlier, on revenues of just $0.9 million for the quarter. Cash and equivalents fell to only $0.725 million from $3.0 million at year-end 2025, while total liabilities stand at $122.4 million against a stockholders' deficit of $56.7 million. The company disclosed substantial doubt about its ability to continue as a going concern for at least one year from the filing date, stating its existing liquidity is not sufficient to fund operations until it reaches significant revenues.
Key figures
- Total Debt
- 64511000
- Cash Position
- 725000
- Shares Outstanding
- 1811970770
- Q3 revenue
- 883000
- Total liabilities
- 122441000
- Nine month g and a
- 19843000
- Nine month r and d
- 14785000
- Nine month revenue
- 2184000
- Subsequent event loan
- 5505000
- Standby equity facility
- 50000000
- Debt extinguishment loss nine months
- 9980000
- Shares issued for debt conversion nine months
- 117.4 million shares for $21.5 million of convertible notes at weighted average $0.18 per share
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.